INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWPRNewsWire • 08/16/25
Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a BetZacks Investment Research • 08/15/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWGlobeNewsWire • 08/09/25
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 08/04/25
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025GlobeNewsWire • 07/29/25
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United StatesBusiness Wire • 07/17/25
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United StatesBusiness Wire • 07/17/25
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 07/15/25
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It UpSeeking Alpha • 07/11/25
Harrow Appoints Mike Biega as Vice President of Investor Relations and CommunicationsBusiness Wire • 06/18/25
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa PharmaceuticalsBusiness Wire • 06/09/25